Akari Therapeutics PLC said CEO and director David Solomon resigned following an internal investigation that revealed he used the company's credit card for personal use.

Akari said it found Solomon violating the drugmaker's policies after incurring personal charges on the company's corporate credit cards.

Clive Richardson, Akari's COO, will head the company in the interim as it searches for a permanent CEO.

The news comes nearly a year after the drugmaker's previous CEO, Gur Roshwalb, resigned after having been found of violating a company policy.